FDA Clearance Tracker · P220034
LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
Last checked: Nov 19, 2026Latest source record: Mar 29, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Mar 29, 2024
Approved
Time to decision
458 days
Received Dec 27, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P220034
- Device name
- LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus
- Applicant
- DiaSorin, Inc.
- Applicant location
- Stillwater, MN
- Received
- Dec 27, 2022
- Decided
- Mar 29, 2024
- Decision
- Approved
- Supplements
- 10 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for LIAISON Biotrin Parvovirus B19 IgG Plus and LIAISON Biotrin Control Parvovirus B19 IgG Plus. The LIAISON Biotrin Parvovirus B19 IgG Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgG antibodies to B19 virus (B19V, previously known as human parvovirus B19) in human serum, lithium heparin, dipotassium EDTA (K2-EDTA), and sodium citrated plasma. The test may be used for testing women of childbearing age where there is a suspicion of exposure to human B19V. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MYL. The earliest in FDA's data is P970054, decided Aug 6, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for DiaSorin, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260770 · Decided Jun 4, 2026 · 87 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
P250039 · Decided May 7, 2026 · 220 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM (MYM) · Laboratory Medicine & Pathology
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)New device typeBreakthroughDe Novo
DEN250032 · Decided Dec 23, 2025 · 146 days after receipt
Device type: Device To Detect Antibodies To Hepatitis D Virus (SGW) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.